Multitarget-directed cotreatment with cilostazol and aripiprazole for augmented neuroprotection against oxidative stress-induced toxicity in HT22 mouse hippocampal cells.
This study highlights that cotreatment with low concentrations of aripiprazole and cilostazol synergistically elicits neuroprotective effects by overcoming oxidative stress-evoked neurotoxicity associated with increased neurite outgrowth, providing a rationale for the use of this combinatorial treatment in vascular dementia.
PMID: 31202803 [PubMed - as supplied by publisher]
Source: European Journal of Pharmacology - Category: Drugs & Pharmacology Authors: Lee YS, Park SY, Heo HJ, Lee WS, Hong KW, Kim CD Tags: Eur J Pharmacol Source Type: research
More News: Abilify | Brain | Cilostazol | Dementia | Drugs & Pharmacology | Gleevec | Neurology | Neuroscience | Science | Study | Toxicology